Similar articles

• Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study.

  Bodri D, Guillén JJ, Trullenque M, Schwenn K, Esteve C, Coll O. Bodri D, et al. Fertil Steril. 2010 May 1;93(7):2418-20. doi: 10.1016/j.fertnstert.2009.08.036. Epub 2009 Oct 2. Fertil Steril. 2010. PMID: 19800620 Clinical Trial.
• GnRH antagonists in poor responders.

  Kolibianakis E, Albano C, Zikopoulos K, Kahn JA, Van Steirteghem A, Devroey P. Kolibianakis E, et al. Acta Obstet Gynecol Scand. 2004 Dec;83(12):1216-7. doi: 10.1111/j.0001-6349.2004.00480.x. Acta Obstet Gynecol Scand. 2004. PMID: 15548159 No abstract available.
• [In vitro fertilization and embryo transfer].

  Saito H, Nakagawa K, Kojima R, Takahashi Y. Saito H, et al. Nihon Rinsho. 2006 Apr;64 Suppl 4:80-4. Nihon Rinsho. 2006. PMID: 16689289 Review. Japanese. No abstract available.
• [Clinical application of gonadotrophin for IVF-ET].

  Kajihara T, Ishihara O. Kajihara T, et al. Nihon Rinsho. 2006 Apr;64 Suppl 4:237-41. Nihon Rinsho. 2006. PMID: 16689315 Review. Japanese. No abstract available.
• Premature ovarian failure: clinical presentation and treatment.

  Kovanci E, Schutt AK. Kovanci E, et al. Obstet Gynecol Clin North Am. 2015 Mar;42(1):153-61. doi: 10.1016/j.ogc.2014.10.004. Obstet Gynecol Clin North Am. 2015. PMID: 25681846 Review.